P. Hemachandra Reddy

I have expertise in the following: 1) making and characterizing transgenic mouse models, 2) twelve years of experience in IACUC, 3) growing and characterizing and live-cell imaging of primary neuronal cultures, 4) axonal transport of subcellular organelles, including mitochondria and synaptic vesicles, and twenty five years of genetics, cell and molecular biology.

Since 2001, teaching high school, undergraduate, postgraduate students and pre- and postdoctoral scholars.

None.

2003-present: Ad Hoc Reviewer of Journal of Neurochemistry
2003-present: Ad Hoc Reviewer of Biotechniques
2003-present: Ad Hoc Reviewer of Briefings of Functional Genomics and Proteomics
2003-present: Ad Hoc Reviewer of Trends in Genetics
2004-present: Ad Hoc Reviewer of Journal of Neuroscience Methods
2004-present: Ad Hoc Reviewer of Journal of Neuroscience
2005-present: Ad Hoc Reviewer of Journal of Alzheimer’s Disease
2005-present: Ad Hoc Reviewer of Mitochondrion
2005-present: Ad Hoc Reviewer of Developmental Brain Research
2005-present: Ad Hoc Reviewer of Brain Research
2005-present: ad Hoc Reviewer of Brain Research Reviews
2005-present: Ad Hoc Reviewer of Neurobiology of Aging
2006-present: Ad Hoc Reviewer of Neuroscience
2007-present: Ad Hoc Reviewer of Rejuvenation Research
2007-present: Ad hoc Reviewer of Antioxidants and Redox Signaling
2007-present: Ad Hoc Reviewer of Trends in Molecular Medicine
2007-present: Ad Hoc Reviewer of Annals of Neurology
2007-present: Ad Hoc Reviewer of Journal of Neurology
2007-present: Ad Hoc Reviewer of Experimental Neurology
2007-present: Ad Hoc Reviewer of Antioxidants & Redox Signaling
2008-present: Ad Hoc Reviewer of Trends in Pharmacological Sciences
2008-present: Ad Hoc Reviewer of Open Longevity Science
2008-present: Ad Hoc Reviewer of Nature Medicine
2009-present: Ad Hoc Reviewer of PLOS One
2009-present: Ad Hoc Reviewer of World Journal of Gastrointestinal Pharmacology and Therapeutics
2010-present: Ad Hoc Reviewer of Neurobiology of Disease
2010-present: Ad Hoc Reviewer of Metabolic Brain Disease
2010-present: Ad Hoc Reviewer of Frontiers in Neuropharmacology
2010-present: Ad Hoc Reviewer of Mini-Reviews in Medicinal Chemistry
2010-present: Ad Hoc Reviewer of Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry
2010-present: Ad Hoc Reviewer of Current Alzheimer Research
2011-present: Ad Hoc Reviewer of The Journal of Pharmacognosy
2011-present: Ad Hoc Reviewer of Journal of Gerontology: Biological Sciences
2011-present: Ad-Hoc Reviewer of Clinical Practice
2011-present: Ad Hoc Reviewer of World Journal of Methodology

Editorial Board
2011-2014: Associate Editor of Journal of Alzheimer’s Disease
2009-present: Associate Editor of Frontiers in Aging Neuroscience
2010-present: Associate Editor Journal of Gerontology: Biological Sciences
2011-present: Associate Editor of Clinical Practice
2011-present: Section Editor BBA-Molecular Basis of Disease
2011-present: Academic Editor of PLoS ONE

Guest Editor
Guest Editor for 2 special issues in Pharmaceuticals-
1. Mitochondrial Drugs for Neurodegenerative Disease and
2). Genes, Mechanisms and Drugs for Asthma in journal, Pharmaceuticals – Molecular Diversity Preservation International (MDPI)

Guest Editor for a special issue ‘Current Status of Therapeutics and Preventive Measures for Patients with Thalassaemia and Sickle Cell Disease’ for Cardiovascular & Hematological Agents in Medicinal Chemistry

Guest Editor for a special issue ‘Aging and Mitochondria in Alzheimer’s Disease in Antioxidants & Redox Signaling.

Guest Editor for a special issue ‘Synaptic Damage in Aging and Neurodegenerative Diseases’ in Frontiers in Aging Neuroscience

Guest Editor for a special issue ‘Misfolded Proteins, Mitochondrial Dysfunction and Neurodegenerative Disease’ in BBA Molecular Basis of Disease.

Editorial Board
2008-present: Open Longevity Science Journal
2009-present: Frontiers in Aging Neuroscience
2009-present World Journal of Gastrointestinal Pharmacology and Therapeutics
2009-present: Cardiovascular & Hematological Agents in Medicinal Chemistry
2009-present: Pharmaceuticals
2010-present: Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry
2010-present Frontiers in Neuropharmacology
2010-present: BBA Molecular Basis of Disease
2010-present: Metabolic Brain Disease
2010-present: Mini-Reviews in Medicinal Chemistry
2010-present: Current Alzheimer Research
2011-present: Journal of Alzheimer Disease
2011-present: PLOS ONE
2011-present: The Journal of Pharmacognosy
2011-present: World Journal of Methodology
2011-present: World Journal of Translational Medicine
2011-present: Journal of Physiology and Pharmacology Advances
2012-present: Antioxidants (MDPI)

2012: Opponent (external examiner) for a doctoral thesis from Karolinska Institute, Stockholm, Sweden.
2011: Academic Editor for PLOS ONE
2011: Forum/Guest Editor for a special issue – Aging and Mitochondria in Alzheimer’s Disease (for Antioxidants & Redox Signaling).
2009: Guest Editor of a Special Issue – Synaptic Damage in Aging and Neurodegenerative Diseases
(for Frontiers in Aging Neuroscience)
2009: Guest Editor of Special Issues – Mitochondrial Drugs for Neurodegenerative Disease and Genes, Mechanisms and Drugs for Asthma (Pharmaceuticals – Molecular Diversity Preservation International (MDPI)
2009-present: Associate Editor, Frontiers in Aging Neuroscience
2007-Technology Transfer Innovations Award from Oregon Health and Science University
2006- Alzheimer Award for an outstanding paper “Differential loss of synaptic proteins in Alzheimer’s disease: Implications for synaptic dysfunction” published in Journal of Alzheimer’s disease 7, 103-117
2003- Mentor Appreciation Award from Oregon Health and Science University
1999- Won a travel fellowship from Huntington’s Disease Society of America (HDSA) & presented a paper at 18th International Meeting of the World Federation of Neurology Research Group on Huntington’s Disease held in Hague, Netherlands, August 28-31, 1999
1999 - Fellows Award for Research Excellence (FARE Award) 1999 in Biomedical Research from National Institutes of Health, Bethesda, Maryland, USA
1999- 2000 Huntington Disease Society of America fellow
1995-1999: Visiting Fellowship from Fogarty International at National Institutes of Health (NIH), USA.
1994-1995; University College London post-doctoral Fellowship
1993-1994 Sir Halley Stewart Trust grant for laboratory expenses
1990-1994 Stopes Research Fund from Galton Institute, London, for field and laboratory expenses.
1990-1993 Commonwealth Scholarship from Great Britain, London
1985-1987 Junior Research Fellowship from Department of Science and Technology, Delhi

1. Invited talk entitled ‘Genetic and Mitochondrial Determinants of Synaptic Dysfunction in Neurodegenerative Diseases’ at the 23rd Neuropharmacology Conference of The Synaptic Basis of Neurodegenerative Diseases, and A satellite meeting to Society for Neuroscience to be held at San Diego 7-8 November 2013.

2. Invited talk entitled ‘Mitochondria-Targeted Drugs To Treat Patients With Alzheimer’s Disease’ on June 5, at the Drug Discovery and Therapy World Congress at the John B. Hynes Veterans Memorial Convention Center, June 3-6, 2013, Boston.

3. Invited talk entitled ‘Are Mitochondria Critical For Synaptic Activity and Neuronal Function in Alzheimer’s Disease’? at the Wellesley College Summer Research Program on June 6, 2013, Wellesley.

4. Invited talk ‘Drug Screening – Fusion/Fission Modulators’ at the Neuromuscular Disorders of Mitochondrial Fusion and Fission to be held European Neuromuscular Center, in NH Naarden Hotel, The Netherlands, April 26-28, 2013.

5. Invited talk ‘Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease’ at the Research in Anesthesiology and Peri-operative Medicine Department of Oregon Health and Science University, February 6, 2013.

6. Invited talk entitled ‘Mitochondria-Targeted Catalase Reduces Abnormal APP Processing, Amyloid beta Production and BACE1 in a Mouse Models of Alzheimer’s Disease: Implications for Neuroprotection and Lifespan Extension’ at the 7th International Conference of the Coenzyme Q10, held in Seville - Spain, November 8-11, 2012.

7. Invited talk entitled ‘Amyloid Beta Induced Impaired Mitochondrial Dynamics and Synaptic Degeneration in Alzheimer’s Disease’ by Dr. Qitao Ran, Barshop Institute of Aging, University of Texas Health Center, San Antonio, September 25-27, 2012.

8. Invited talk entitled ‘Amyloid Beta and Mitochondria in Alzheimer’s Disease’ by Dr. Maria Ankarcrona, Alzheimer’s Disease Center, Karolinska Institute, Stockholm, Sweden, September 11-16, 2012.

9. Invited talk entitled ‘Mitochondria as Drug Targets’ at a Symposium on Alzheimer`s Disease: New perspectives on therapeutic targets and pathways’ held in Frankfurt, Germany, August 25-27, 2011.

10. Invited faculty seminar entitled “Abnormal Mitochondrial Dynamics and Synaptic Damage in Alzheimer’s Disease: Implications Cognitive Decline” by Dr. Susan Hayflick, Chair of Medical and Molecular Genetics Department, Oregon Health and Science University, December 1, 2010.

11. Invited faculty seminar entitled “Abnormal Mitochondrial Dynamics in Alzheimer’s Disease: Implications for Synaptic Damage and Cognitive Decline” by Dr. Domenico Pratico of Pharmacology Department, Temple University School of Medicine, Philadelphia, November 3, 2010.

12. Invited talk entitled “Oxidative Stress and Mitochondria-Targeting Antioxidants” by EISAI at Mitochondrial Advisory Symposium held at Hatfield, London, September 13-15, 2010.

13. Invited talk entitled “Mitochondrial Medicine for Cognitive Aging and Alzheimer's Disease” by New York academy of Sciences and Alzheimer’s Drug Discovery Foundation held at New York on May 13, 2010.

14. Invited talk entitled “Role of Amyloid Beta and Mitochondrial Dysfunction in Alzheimer’s Disease” by Dr. Ian Murray from Texas A&M University College Station, TX February 11, 2010

15. Invited talk entitled “Mitochondrial Dysfunction in Aging and Alzheimer’s Disease” by Drs. Qitao Ran and Yidong Bai from University of Texas Health Science Center, San Antonio, November 30, 2009.

16. Invited talk entitled “Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer’ Disease” by David Nicholls, chair of Gordon Research Conference on Molecular and Cellular Bioenergetics to be held at Proctor Academy, Andover, New Hampshire, June 7-12, 2009.

17. Invited talk entitled “Mitochondria in Aging and Alzheimer’s Disease” by Dennis Bourdette, Chair of Neurology, Oregon Health and Science University, April 21, 2008.

18. Invited talk entitled “Amyloid beta and mitochondrial dysfunction in the development and progression of Alzheimer’s disease: implications for mitochondrial therapeutics” at 5th International Congress on VASCULAR DEMENTIA held at Budapest, Hungary November 8-11, 2007.

19. Invited seminar entitled “Mitochondrial Dysfunction in Aging and Alzheimer’s disease: Strategies to Protect Neurons” by Flint Beal, Cornell University, New York, July 17-18, 2007.

20. Invited seminar on Alzheimer’s Disease entitled “Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial and apoptotic genes is an early cellular change in Alzheimer’s disease” by Rod. Capaldi, University of Oregon, Eugene in October 2003.

21. Invited seminar on Alzheimer’s disease entitled “Gene expression profiles in Alzheimer’s disease patients” by Oregon National Primate Research Center, Oregon Health Sciences University, 17th April 2001.

22. Invited seminar on “Gene expression profiles of transcripts in Alzheimer’s disease” by Alzheimer’s disease Center, Oregon Health Sciences University, Portland, Oregon, on January 2000.

23. Invited seminar on Huntington’s disease entitled “ Transgenic mouse models for Huntington’s
disease: Mechanisms of neurodegeneration and psychosis” by Neurological Sciences Institute, Oregon
Health Sciences University, Portland, Oregon, on 13th October, 1999.

24. Invited seminar on Huntington’s disease entitled “In Vivo Models for Huntington’s disease” by
Sanders Brown Center on Aging, University of Kentucky, Lexington on 22nd March, 1999.

25. Invited seminar on Huntington’s Disease entitled “Mouse Models for Huntington’s disease” by
McLaughlin Research Institute, Great Falls, Montana on 4th June, 1999.

Attended and organized several workshops and trainings.

Reading, writing and watching cricket.

Peer-reviewed Publications
Mao P, Manczak M, Shirendeb UP and Reddy PH (2013) MitoQ, a mitochondria-targeted antioxidant delays disease progression and extends lifespan in an experimental autoimmune encephalomyelitis mouse model of Multiple Sclerosis. Submitted to BBA Molecular Basis of Disease.
Manczak M and Reddy PH (2013) RNA Silencing of Genes involved in Alzheimer’s Disease Enhance Mitochondrial Function and Synaptic Activity. Submitted to BBA Molecular Basis of Disease.
Reddy PH (2013) Amyloid beta-induced Glycogen Synthase Kinase 3β phosphorylated VDAC1 in Alzheimer’s Disease: Implications for Synaptic Dysfunction and Neuronal Damage. BBA Molecular Basis of Disease (in press).
Manczak M, Sheiko T, Craigen WJ and Reddy PH (2013) Reduced VDAC1 Protects Against Alzheimer’s Disease, Mitochondria and Synaptic Deficiencies. Journal of Alzheimer’s Disease (in press).
Manczak M and Reddy PH (2013) Abnormal interaction of oligomeric amyloid beta with phosphorylated tau: Implications to neuronal damage. Journal of Alzheimer’s Disease (in press).
Mao P, Meshul CK, Thuillier P and Reddy PH (2013) Neurotransmitter CART as a new therapeutic candidate for Parkinson's disease. Pharmaceuticals. 6, 108-123.
Reddy PH (2013) Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease? Biochim Biophys Acta. 1832, 67-75.
Calkins MJ, Manczak M, Reddy PH (2012) Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer's Disease. Pharmaceuticals (Basel). 5, 1103-1119.
Manczak M, Reddy PH (2012) Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet.;21, 5131-5146.
Mao P, Manczak M, Calkins MJ, Troung Q, Reddy TP, Reddy AP, Shirendeb UP, Lo HH, Rabinovitch Reddy PH (2012) Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production, and BACE1 in a mouse model of Alzheimer’s disease: Implications for neuroprotection and lifespan extension. Hum Mol Genet 21, 2973-2990.
Kageyama K, Zhang Z, Roda R, Fukaya M, Wakabayashi J, Wakabayashi N, Kensler TW, Reddy PH, Dawson, TM, Iijima M, and Sesaki H (2012) Mitochondrial Division Ensures the Survival of Postmitotic Neurons by Suppressing Oxidative Damage. J Cell Biol 197, 535-551.
Manczak M, Sesaki H, Kageyama Y, Reddy PH (2012). Dynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficiencies. Biochim Biophys Acta. 1822, 862-874.
Manczak M, Reddy PH (2012). Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet. 21, 2538-2547.
Reddy PH (2012). Current Status of Therapeutics and Preventive Measures for Patients with Thalassaemia and Sickle Cell Disease. Cardiovasc Hematol Agents Med Chem. 10, 2. Editorial
Mao P, Meshul C, Thuiller P, Goldberg NRS, Reddy PH (2012). CART peptide is a potential endogenous antioxidant and preferentially localized in mitochondria PLoS One 7, e29343
Reddy PH and Shirendeb UP (2012). Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta 1822,101-110.
Mao P, Gallagher P, Nedungadi S, Manczak M, Shirendeb UP, Kohama SG, Ferguson B, Park BS, Reddy PH (2012). Mitochondrial DNA deletions and differential mitochondrial DNA content in Rhesus monkeys: Implications for aging. Biochim Biophys Acta. 1822, 111-119.
Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, Manczak M (2012). Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta. 1822, 639-639.
Shirendeb UP, Calkins M, Manczak M, Anekonda V, Dufour B, McBride J, Mao P and Reddy PH (2012) Mutant huntington’s association with mitochondria protein Drp1, and impaired axonal transport of mitochondria in Huntington’s disease neurons. Hum Mol Genet 21, 406-420.
Calkins MJ, Manczak M, Mao P, Shirendeb U and Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum Mol Genet. 20, 4515-4529.
Ricoy UM, Mao P, Manczak M, Reddy PH, Frerking ME (2011) A transgenic mouse model for Alzheimer's disease has impaired synaptic gain but normal synaptic dynamics. Neurosci Lett. 500, 212-215.
Reddy PH (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res. 1415:136-148.
Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics. Biochim Biophys Acta. 2011 Aug 18;1812(11):1359-1370.
Calkins MJ, Reddy PH (2011) Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. Biochim Biophys Acta. 1812, 1182-1189.
Reddy PH, Reddy TP (2011) Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases. Curr Alzheimer Res. 8, 393-409.
Reddy PH (2011) Mitochondrial Dysfunction and Oxidative Stress in Asthma: Implications for Mitochondria-Targeted Antioxidant Therapeutics. Pharmaceuticals (Basel). 4, 429-456.
Manczak M, Calkins MJ, Reddy PH (2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet. 20, 2495-2509.
Reddy TP, Manczak M, Calkins MJ, Mao P, Reddy AP, Shirendeb U, Park B, Reddy PH (2011) Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant SS31. Int J Environ Res Public Health. 8, 203-221.
Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet. 20, 1438-1455.
Calkins MJ, Reddy PH (2011) Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim Biophys Acta. 1812, 507-513. Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U, Mao P (2011) Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev. 67, 103-118. Reddy PH, M Manczak, P Mao, Calkins M, Reddy AP, Shirendeb U (2010) Amyloid-β and Mitochondria in Aging and Alzheimer’s Disease: Implications for Synaptic Damage and Cognitive Decline J. Alzheimer’s Disease 20 Suppl 2:S499-512.
M Manczak, P Mao, Calkins M, A Cornea, Reddy AP, M Murphy, HH Szeto, Park BS and PH Reddy (2010) Mitochondria-targeted antioxidants protect against Abeta toxicity in Alzheimer’s disease neurons J. Alzheimer’s Disease 20 Suppl 2:S609-631.
P Mao and PH Reddy (2010) Is Multiple Sclerosis a Mitochondrial Disease? BBA Molecular mechanisms of disease. 1802,66-79 (Invited).
PH Reddy, M Manczak, K Nakamura, P Mao, Bebbington C, Yarranton G and W Zhao (2009 Neutralization of the granulocyte macrophage colony-stimulating factor suppresses microglia activity: Implications for anti-inflammatory effects in Alzheimer’s Disease and Multiple Sclerosis. Journal of Neurochemistry 111, 1514-1528.
PH Reddy (2009) Role of Mitochondria in neurodegenerative diseases: Mitochondria as a therapeutic target in Alzheimer’s disease. CNS Sprectrums 14:8 (Suppl 7) 8-13 (Invited).
M Manczak, P Mao, K Nakamura, C Bebbington, BS Park and PH Reddy (2009) Neutralization of granulocyte macrophage colony stimulating factor decreases Amyloid beta 1-42 and suppresses microglial activity in transgenic mouse model of Alzheimer’s Disease. Human Molecular Genetics 18, 3876-3893.
PH Reddy, P Mao and M Manczak (2009) Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Research Reviews 61, 33-48.
PH Reddy (2009) Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer’s disease. Experimental Neurology Invited article 218, 2286-2292.
PH Reddy (2008) Mitochondrial Medicine for Aging and Neurodegenerative Diseases. NeuroMolecular Med. 10, 291-315.
PH Reddy and MF Beal (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications to cognitive decline in aging and Alzheimer’s disease. Invited article by Trends in Molecular Medicine 14, 45-53 (Invited).
PH Reddy (2007) Mitochondrial dysfunction in aging and Alzheimer’s disease: Strategies to Protect Neurons. Invited Article by Antioxidants & Redox Signaling 9, 1647-1658 (invited).
MF Beal, E Bossy-Wetzel, S Finkbeiner, G Fiskum, B Giasson, C Johnson, ZS Khachaturian, VM.-Y. Lee, D Nicholls, PH Reddy, IJ Reynolds, DB. Teplow, LJ. Thal, JQ Trojanowski, DM Walsh, R Wetzel, NS Wexler, AB Young, Bain L (2006). Common Threads in Neurodegenerative Disorders of Aging. Alzheimer’s & Dementia. 4, 322-326.
M Manczak, TS Anekonda, BS Park, E Henson, J Quinn and PH Reddy (2006). Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
PH Reddy (2006) Mitochondrial oxidative damage in aging and Alzheimer’s disease: implications to mitochondrially targeted antioxidants. Journal of Biomedicine and Biotechnology, Volume 2006, Article ID 31372, 13 pages (Invited).
PH Reddy and S McWeeney (2006) Mapping cellular transcriptosomes in autopsied Alzheimer’s disease brain subjects and in relevant animal models. Neurobiology of Aging 27, 1060-1077.
TS Anekonda and PH Reddy (2006) Neuronal protection by Sirtuins in Alzheimer’s Disease. Journal of Neurochemistry. 96, 305-313.
PH Reddy (2006) Amyloid precursor protein mediated free radical generation: implications to development and progression of Alzheimer’s disease. Journal of Neurochemistry 96, 1-13.
TS Anekonda and PH Reddy (2005) Can herbs provide a new generation of drugs for Alzheimer’s Disease?. Brain Research Reviews 50, 361-376.
PH Reddy and MF Beal (2005) Are mitochondria critical in the pathogenesis of Alzheimer’s disease. Brain Research Reviews. 49, 618-632.
JA Sayer, M Manczak, L Akilesawran PH Reddy and V Coghlan (2005) Interaction of the nuclear matrix protein NAKAP with HypA and Huntingtin. Implications for nuclear toxicity in Huntington’s disease pathogenesis. NeuroMolecular Medicine. 7, 297-310.
PH Reddy, G Mani, BS Park, J Jacques, G Murdoch, W Whetsell Jr., JA Kaye, and M Manczak (2005) Differential loss of synaptic proteins in Alzheimer’s disease: Implications for synaptic dysfunction. Journal of Alzheimer’s Disease 7, 103-117.
M Manczak, Y Jung, BS Park, D Partovi and PH Reddy (2005) Time-course mitochondrial gene expressions in mice brains: Implications to mitochondrial dysfunction, oxidative damage and cytochrome c release in aging. Journal of Neurochemistry 92, 494-504.
RV Gutala and PH Reddy (2004). The use of real-time PCR analysis in a gene expression study of Alzheimer’s disease postmortem brains. Journal of Neurosci Methods 132,101-107.
M Manczak, BS Park, Y Jung and PH Reddy (2004) Differential expression of oxidative phosphorylation genes in Alzheimer’s disease patients: Implications for early mitochondrial dysfunction and oxidative damage. NeuroMolecular Medicine. 5, 147-162.
PH Reddy, S McWeeney, M Manczak, BS Park, RV Gutala, Y Jung, Yau V, R Searles, M Mori and J Quinn (2004) Gene expression profiles of transcripts in amyloid precursor protein transgenic Mice: Upregulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Published in Hum Mol Genet 13, 1225-1240.
VV Senatorv, V Charles, PH Reddy, DA Tagle, and D-M Chuang (2003) Abnormal expression of glutaraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington’s disease. Molecular and Cellular Neuroscience 22, 285-297.
GA Laforet, E Sapp, K Chase, C McIntyre, FM Boyce, M Campbell, BA Cadigan, L Warzecki, DA Tagle, PH Reddy, C Cepeda, CR Calvert, ES Jokel, GJ Clapstein, MA Ariano, MS Levine, M DiFiglia, Aronin NA (2001) Changes in Cortical and striatal neurons predict behavioral and electrophysiological abnormailities in a transgenic murine model of Huntington’s disease. Journal of Neuroscience. 21, 9112-9123.
A Savanenin, Y Sun, PH Reddy and YF Liu (2001) Polyglutamine expanded Huntingtin promotes sensitization of NMDA receptor via post-synaptic associated protein 95. Journal of Biological Chemistry. 276, 24713-24718.
P. Guidetti, V Charles, Er-Yun Chen, PH Reddy, HJ Kordewer, WO Whetsell Jr., R Schwarcz and DA Tagle (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production Exp Neurol. 169, 340-350.
P Guidetti, PH Reddy, DA Tagle and R Schwarcz (2000) Early Kynurenergic impairment in Huntington’s disease and in a transgenic mouse model. Neurosci lett 283, 233-235.
SS Mastana, PH Reddy, MK Das, and PA Reddy (2000). Molecular genetic diversity in five populations in India. Hum Biol 72, 499-510.
V Charles, E Mezey, PH Reddy, A Deheja, , MH Polymeropoulos, M Brownstein and DA Tagle (2000) In vivo interaction of alpha synuclein protein with huntingtin. Neurosci Lett 289, 28-32.
PH Reddy, V Charles, M. Williams, G. Miller, WO Whetsell Jr, and DA Tagle (1999) Transgenic mice expressing mutated full-length cDNA: A paradigm for locomotor changes and selective neuronal loss in Huntington’s Disease. Phil Trans Royal Socie. 1386, 1035-1046.
PH Reddy, M. Williams and DA Tagle (1999) Recent advances in understanding Huntington’s Disease pathogenesis. Trend Neurosci 22, 248-255.
M Kim, HS Lee, G LaFooret, C McIntyre, EJ Martin, P Chang, TW Kim, P Bhide, M Williams, PH Reddy DA Tagle, FM Boyce, L Won, A Heller, N Aronin and M DiFiglia (1999) Mutant huntingtin expressing in clonal striatal cells: Effects of caspase inhibition on inclusion formation and neuronal survival. J Neurosci 19, 964-973.
PH Reddy, M Williams, V Charles, L Garrett, LP Buchanan, WO Whetsell Jr, G Miller and DA Tagle (1998) Behavioral abnormalities and selective neuronal loss in transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20, 198-202.
PH Reddy and B Modell (1997) The Baigas of Madhya Pradesh: a demographic study. Journal of Biosocial Science 29, 19-31.
PH Reddy and B Modell (1996) Reproductive behaviour and natural selection for the sickle cell gene: the role of social parenting. Annals of Human Genetics 60, 231-236.
SS Mastana, R Calderon, J Pena, PH Reddy, and SS Papiha (1998) Anthropology of Apolipoprotein (Apo E) gene: low frequency of ApoE4 allele in Basque and tribal (Baiga) populations of India. Annal Hum Biol. 25, 137-143.
PH Reddy, E Stockburger, P Gillevet and DA Tagle (1997) Characterization of novel (CAG)n repeat containing cDNAs from adult human brain derived by oligo capture method. Genomics 46, 174-182.
JS Kaeda, GP Chotray, MR Ranjit, PH Reddy, D Stevens, JM Naidu, RP Britt, TJ Vulliamy, L Luzzatto and PJ Mason (1995) A new glucose-6-phosphate dehydrogenase (G6PD) variant, G6PD Orissa (44 Ala-Gly), is the major polymorphic variant in tribal populations in India. American Journal of Human Genetics 57, 1335-1341.
PH Reddy, M Petrou, PA Reddy, RS Tiwary, and B Modell (1995) Hereditary anaemias and iron deficiency in a tribal population (the Baiga) of Central India. Eur J Haematol 55, 103-109.
PH Reddy and B Modell (1995). Consanguinity and reproductive behaviour in a tribal population “the Baiga” in Madhya Pradesh, India. Annal Hum Biol. 22, 235-246.
PH Reddy and RS Tedder (1995). Hepatitis virus markers in the Baiga tribal population of Madhya Pradesh, India. Trans Royal Socie Trop Med and Hyg 89, 260.7.
PH Reddy and SS Mastana (1995). Genetic variation of serum proteins (GC, TF and PI) subtypes in the Baigas of Madhya Pradesh, India. Anthrolopogical Anziener 53, 53-56.
PH Reddy and B Modell (1992). Hereditary anaemias and tribal populations in India. Galton Institute Newsletter 4, 5.

Book Chapters
PH Reddy (2010) Neurogenetics of Aging (Chapter 3) in Clinical Neurology of Aging Edited by Martin Albert Janice Knoefel, Oxford University Publications.
PH Reddy, V Charles, WO Whetsell Jr and DA Tagle (2001). Behavioural changes and selective neuronal loss in full-length transgenic mouse models for Huntington Disease. Edited by PS Harper and M Perutz. In, polyglutamine repeats and neurodegenerative diseases. Oxford University Publications, Pages 41-64.
PH Reddy and DA Tagle (1999). The Biology of Trinucleotide repeat diseases. Edited by M. Mattson. In, Genetic aberrancies and neurodegenerative diseases. (Jai Publications), Advances in Cell Aging and Gerontology, Volume 3, Pages 33-79.

Book Reviews
PH Reddy (2004). Huntington’s Disease - Edited by Gillian Bates, Peter S. Harper and Lesley Jones, Oxford Publications. Book Review. American Journal of Human Genetics. 74,781-782.

Invited Commentaries in Alzheimer Research Forum
1. Wrote an invited commentary on Science article by Schriner SE, Linford NJ, Martin GM, Treuting P
Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, Rabinovitch PS
Extension of Murine Lifespan by Overexpression of Catalase Targeted to Mitochondria. Science. 2005:
308, 1909-1911.

2. Wrote an invited commentary on JBC article by Falkevall A, Alikhani N, Bhushan S, Pavlov PF, Busch K, Johnson KA, Eneqvist T, Tjernberg L, Ankarcrona M, Glaser E. Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP. J Biol Chem. 2006: 281, 29096-29104.

3. Wrote an invited commentary on Nature Medicine article by Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuated mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nature Medicine 2008: 14, 1097-1105.

4. Wrote an invited commentary on PNAS article by Massaad CA, Washington TM, Pautler RG, Klann E. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13576-81.

5. Wrote an invited commentary on PLOSONE article by Sanz-Blasco S, Valero RA, Rodríguez-Crespo I, Villalobos C, Núñez L. Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE. 2008;3(7):e2718.

6. Wrote an invited commentary on Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, Lee VM. Intraneuronal APP, not free Aß peptides in 3xTg-AD mice: implications for tau versus Aß-mediated Alzheimer neurodegeneration. J Neurosci. 2011 May 25;31(21):7691-7699.